Study Suggests Breast Cancer Screening Options for Women With ATM, CHEK2, and PALB2 Mutations Mar 22, 2022 Women with ATM, CHEK2, or PALB2 mutations may benefit from starting annual breast cancer screening with MRI between the ages and 30 to 35 and an annual MRI and mammogram starting at age 40. Read more...
Lynparza Approved To Treat High-Risk, Early-Stage, HER2-Negative Breast Cancer With BRCA Mutation Mar 13, 2022 The FDA approved Lynparza to treat early-stage, HER2-negative breast cancer with a BRCA1 or BRCA2 mutation and a high risk of recurrence, which also has been previously treated with chemotherapy — either before or…